Mallinckrodt Launches Scientific Advisory Council
Joining Dr. Romano as charter members of the SAC are three leading experts in their respective fields, selected, in part, because of their experience and expertise in areas that are central to Mallinckrodt's current portfolio – namely, regenerative medicine, neonatal critical care and autoimmune and rare diseases. The first three external members include:
- Jörg C. Gerlach, MD, PhD, working as a Professor of Surgery and Bioengineering,
McGowan Institute for Regenerative Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Penn.Dr. Gerlach specializes in technologies for the clinical translation of stem cell biology and bioengineering research into cell-based therapies in regenerative medicine. Rashmin C. Savani, MD, ChB, Chief, Division of Neonatal-Perinatal Medicine, Associate Director, Center for Pulmonary and Vascular Biology, Professor and William Buchanan Chair of Pediatrics at University of Texas Southwestern Medical Center in Dallas, Texas. Dr. Savani specializes in neonatal intensive care and lung disorders. Ulrich H. von Andrian, MD, PhD, Edward Mallinckrodt Jr.Chair of Immunopathology and Professor of Microbiology and Immunobiology, Harvard Medical School, Boston, Mass.; Director, Harvard Medical School Center for Immune Imaging. Dr. von Andrian, also the Program Leader in Basic Immunology for Ragon Institute of MGH1, MIT2 and Harvard, specializes in immunotherapy and autoimmune disorders.
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the
Investor Relations and Strategy Officer
Senior Communications Manager
Chief Public Affairs Officer
1 Massachusetts General Hospital
2 Massachusetts Institute of Technology
View original content with multimedia:http://www.prnewswire.com/news-releases/mallinckrodt-launches-scientific-advisory-council-300670456.html